Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Can-Fite Biopharma Ltd American Depositary Shares (NY:CANF)

4.216 -0.144 (-3.31%)
Streaming Delayed Price Updated: 11:04 AM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Can-Fite Biopharma Ltd American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  During Tuesday, 40 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Novel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for Placebo
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  During Friday, 48 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 22 companies hit new 52-week lows. 
Via Benzinga
News headline image
Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been Filed
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 35 companies reached new 52-week lows. 
Via Benzinga
News headline image
Can-Fite Announces ADS Ratio Change
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite's Namodenoson Increases Survival For Most Severe Patients With Advanced Liver Cancer ↗
 
Via Benzinga
News headline image
Can-Fite Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Multiple Shots On Goal: Can-Fite’s Late-Stage Clinical Pipeline Hits Positive Results
By Ernest Dela Aglanu, Benzinga 
Via News Direct
Multiple Shots On Goal: Can-Fite’s Late-Stage Clinical Pipeline Hits Positive Results
Multiple countries are approving Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) ’s Namodenoson for compassionate use in patients with advanced liver cancer. 
Via TheNewswire.com
News headline image
Multiple Shots On Goal: Can-Fite's Late-Stage Clinical Pipeline Hits Positive Results ↗
Multiple countries are approving Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) ’s Namodenoson for compassionate use in patients with advanced liver cancer. 
Via Benzinga
News headline image
Can-Fite’s Partner Vetbiolix is Heading into a European Multicentric Clinical Trial with Piclidenoson for the Treatment of Pets’ Osteoarthritis
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Meet This BioPharma Company With Several Exciting Drugs In Advanced Clinical Trials ↗
Sign up for this week’s All Access giveaway here!  Pnina Fishman, Ph.D., CEO of Can-Fite BioPharma (NYSE: CANF), was a guest on Benzinga’s All Access on Nov 4, 2022. 
Via Benzinga
News headline image
Can-Fite: Positive New Data from it’s Phase III Psoriasis Study will be Presented Today at an Industry Expert Summit in Boston
From Can-Fite BioPharma Ltd.
Via Business Wire
This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers
The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up. 
Via TheNewswire.com
News headline image
This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers ↗
The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up.   
Via Benzinga
News headline image
Can-Fite: Findings Showing the Complete Clearance of Cancer in Patient Treated With Namodenoson Will Be Presented at the AASLD Liver Meeting®
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming Conference
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite BioPharma Ltd. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
Via ACCESSWIRE
News headline image
Can-Fite Reports Second Quarter 2022 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite’s Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Selected to Present the Positive Psoriasis Phase III Data at the 31st European Academy of Dermatology and Venerology Congress
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite: Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through its Partner Vetbiolix
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Smoking Pot Makes You 55% Less Likely To Develop This Deadly Cancer ↗
Marijuana users have 55% fewer chances of developing, one of the most common malignancies worldwide - hepatocellular carcinoma (HCC), according to a study  
Via Benzinga
News headline image
Industry Analysts Seemingly Sing Praises For This Stock After Phase III Trial Results ↗
Psoriasis is a common chronic disease mediated by the immune system. It’s characterized by red, scaly patches that form on the skin. Psoriasis affects more than 3% of the U.S. adult population — over... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.